Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has ...

Exelixis (EXEL) has recently gained traction in the rapidly growing oncology market with its promising pipeline and strong ...

We recently published a list of Kevin O’Leary’s Stock Portfolio: 15 Stock Picks for 2025. In this article, we are going to ...

When Merck reports fourth-quarter earnings, investors are likely to focus on the sales of its blockbuster oncology medicine, ...

Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $97.94 which represents a slight increase of $2.39 or 2.50% from the prior close of $95.55. The stock opened at $96.63 and touched a ...

Merck & Co. Inc. closed 27.25% short of its 52-week high of $134.63, which the company reached on June 25th.

We recently published a list of 12 Best Depressed Stocks to Invest in Now. In this article, we are going to take a look at ...

Last year wasn't a good one for Merck (NYSE: MRK), one of the largest pharmaceutical companies in the world. The healthcare ...

Analysts at Leerink Partnrs issued their FY2029 EPS estimates for shares of Merck & Co., Inc. in a research report issued to clients and investors on Friday, January 24th. Leerink Partnrs analyst D.

Merck & Co Inc (MRK) stock saw a decline, ending the day at $95.55 which represents a decrease of $-1.08 or -1.12% from the prior close of $96.63. The stock opened at $96.79 and touched a low of ...

Co., Inc. (NYSE:MRK), a global healthcare leader, faces a complex landscape of opportunities and challenges as it navigates the competitive biopharmaceutical industry. This comprehensive analysis ...

Merck & Co. Inc. closed 29.03% below its 52-week high of $134.63, which the company reached on June 25th.